Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Dec 19;30(5):488–496. doi: 10.1200/JCO.2011.34.7898

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2011 by American Society of Clinical Oncology

PMC Copyright notice

Fig 3. — Durability of antileukemic activity of navitoclax. (A) The progression-free survival (PFS) for all patients receiving ≥ 110 mg/d navitoclax from study entry (n = 26) is displayed in a Kaplan-Meier plot. (B) PFS for a subset of these patients with fludarabine-refractory disease. Fluorescent in situ hybridization data were available for 22 of 26 patients receiving ≥ 110 mg/d navitoclax. (C) PFS for patients with del17p13.2 chronic lymphocytic leukemia (n = 9), either del17p13.2 or del11p22.3 (n = 16), or chronic lymphocytic leukemia with neither of these abnormalities (n = 6). NA, not applicable.